Literature DB >> 22356103

Haemostatic management of extreme challenges to haemostasis in acquired von Willebrand syndrome.

M P Colella1, G C Duarte, J F C Marques, E V De Paula.   

Abstract

Acquired von Willebrand syndrome (AVWS) is a rare hemorrhagic condition for which very little information is available regarding the management of extreme challenges to Haemostasis. The AVWS is more common in the elderly, who are frequently exposed to invasive procedures and/or chemotherapy. Haematopoietic stem cell transplantation (HSCT) is a situation in which the haemostatic capacity is challenged by severe thrombocytopaenia, chemotherapy-associated mucosal barrier breakdown and the need for invasive procedures. In our report, we present and discuss the haemostatic management of a patient with AVWS who was refractory to Von Willebrand factor concentrate replacement during the course of an autologous HSCT to treat multiple myeloma. Patients with AVWS are frequently exposed to high-risk haemostatic challenges, and additional information about the haemostatic management of these situations is necessary.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22356103     DOI: 10.1111/j.1365-2516.2012.02769.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  3 in total

1.  Acquired von Willebrand syndrome: von Willebrand factor propeptide to von Willebrand factor antigen ratio predicts remission status.

Authors:  Adrienne Lee; Gary Sinclair; Karen Valentine; Paula James; Man-Chiu Poon
Journal:  Blood       Date:  2014-06-20       Impact factor: 22.113

Review 2.  Acquired von Willebrand syndrome: focused for hematologists.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Haematologica       Date:  2020-06-18       Impact factor: 9.941

3.  Acquired von Willebrand syndrome and lymphoproliferative disorders: A case report.

Authors:  Christophe Nicol; Leela Raj; Gaëlle Guillerm; Francis Couturaud; Jean-Richard Eveillard; Brigitte Pan-Petesch
Journal:  Clin Case Rep       Date:  2020-03-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.